Drug interactions
Nilutamide + Pazopanib
Severity: Moderate
Nilutamide and Pazopanib: moderate interaction.
Last updated
For healthcare professionals — reference only. This page is a brief summary, not medical advice and not a substitute for official labeling or clinical judgement. Always verify before prescribing or dispensing.
Summary
Nilutamide is reported to inhibit CYP enzymes and could increase pazopanib exposure, though the effect on CYP3A4 is not well defined. Pazopanib has dose-related hepatotoxicity and QT concerns.
What this interaction means in plain words
Nilutamide and Pazopanib can affect each other. The combination is often manageable, but it may need a change of dose, a change of timing, or extra checks while both are taken.
Nilutamide belongs to Endocrine; Pazopanib belongs to Oncology.
Why it happens
Possible nilutamide inhibition of CYP3A4 reducing pazopanib metabolism; not well established.
What to do
Monitor liver function tests and ECG, and reduce the pazopanib dose if adverse effects emerge.
What to ask your pharmacist
- Should I take them at different times of day?
- Does the dose of either medicine need to change?
- Is there anything I should avoid, such as alcohol or certain foods, while on both?
Pro+ members
Unlock the full page
Create an account and start a Pro+ trial to unlock the full management advice for Nilutamide and Pazopanib, the additional notes, the evidence detail and the whole-prescription interaction checker.
- Full clinical management advice
- Additional notes
- Evidence detail
- Interaction checker for a whole prescription
Try Pro+ free for 14 days on the web. No card needed.
Other interactions of Nilutamide
Other interactions of Pazopanib
- Adagrasib + Pazopanib Major
- Amiodarone + Pazopanib Major
- Amisulpride + Pazopanib Major
- Amobarbital + Pazopanib Major
- Anagrelide + Pazopanib Major
- Apalutamide + Pazopanib Major
Frequently asked questions
Can I take Nilutamide with Pazopanib?
MediHelp rates the interaction as moderate. Nilutamide and Pazopanib can affect each other. The combination is often manageable, but it may need a change of dose, a change of timing, or extra checks while both are taken. Nilutamide is reported to inhibit CYP enzymes and could increase pazopanib exposure, though the effect on CYP3A4 is not well defined. Pazopanib has dose-related hepatotoxicity and QT concerns.
How serious is the interaction between Nilutamide and Pazopanib?
MediHelp rates it moderate, on a four-level scale (minor, moderate, major, contraindicated) based on published labels and references. What to do, in brief: Monitor liver function tests and ECG, and reduce the pazopanib dose if adverse effects emerge.
What other medicines interact with Nilutamide?
MediHelp also lists interactions of Nilutamide with, for example, Dihydroergotamine intranasal, Mavacamten, Artemether / lumefantrine. The full list is on the Nilutamide page.
Full monographs, dosing and an interaction checker in the MediHelp app
Open the complete reference, check multi-drug interactions and use dosing tools in the MediHelp app.
